ArticleClinical & experimental metastasis2004
Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer.
Article in Clinical & experimental metastasis, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Prognostic value of c-Met in colorectal cancer: a meta-analysis.World journal of gastroenterology · 2015Pooled it
- Molecular imaging tracers targeting c-MET: a systematic review of preclinical evidence and clinical translation.European journal of nuclear medicine and molecular imaging · 2026Review
- Enhanced Visualisation of Colorectal Tumours via Topical Application of EMI-137 in a Methylcellulose-Based Formulation: An ex vivo Feasibility Study.Molecular imaging and biology · 2025Article
- Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data.Therapeutic advances in medical oncology · 2024Article
- Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.The oncologist · 2020Article
- Differential miRNA expression profiling reveals miR-205-3p to be a potential radiosensitizer for low- dose ionizing radiation in DLD-1 cells.Oncotarget · 2018Article
- Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.eLife · 2017Article
- Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer.Oncology letters · 2017Article
- Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer.Oncotarget · 2016Article
- Article
- Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors.Theranostics · 2016Article
- Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.The oncologist · 2011Article
- Article
- Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology.The Journal of molecular diagnostics : JMD · 2010Review
- Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering.Tissue engineering. Part A · 2010Article
- Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide.Biochemical and biophysical research communications · 2009Article
- Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.Neoplasia (New York, N.Y.) · 2009Article
- MET as a target for treatment of chest tumors.Lung cancer (Amsterdam, Netherlands) · 2009Review
- c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.Cancer letters · 2008Article
- In vivo detection of c-Met expression in a rat C6 glioma model.Journal of cellular and molecular medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
c-Met, the receptor of hepatocyte growth factor is known to be responsible for the motility and mitogenesis of epithelial cells including cancer cells. To investigate the significance of c-Met expression in human colorectal cancer (CRC), total cellular protein, extracted from 130 CRCs were examined by Western blot analysis. The signal was quantitated by ChemiImager 4000 Low Light Imaging System. c-Met expression was analyzed as the ratio of tumor to matched normal tissue (T/N) and expressed as fold-increase. The cellular localization of c-Met was assessed by immunohistochemistry. The T/N fold increase of c-Met varied from 0.2 to 10.7 with a mean of 3.41 +/- 0.23 (mean +/- SE). 69% primary CRC showed overexpression (T/N > 2.0) of c-Met. Significantly higher c-Met levels were found in CRC with blood vessel invasion (P = 0.04), and in advanced stage (P = 0.04). No relationship was noted between c-Met expression and age, tumor size, location, differentiation. C-Met immunoreactivity was observed in the membrane and cytoplasm of cancer cells. Positive staining of endothelial cells of blood vessels within normal submucosa and tumor was also evident. C-Met protein is expressed at levels significantly higher than adjacent mucosa in most primary adenocarcinomas of the colon. Our results support an important role for c-Met in human CRC progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.